Clinical trial
BCX-1777 in Treating Patients With Refractory Cancer
NCT00073944 · BioCryst Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00073944 |
|---|---|
| Title | BCX-1777 in Treating Patients With Refractory Cancer |
| Official title | Phase I Pharmacology Study Of Oral And Intravenous BCX-1777 In Patients With Refractory T-Cell And Non-T-Cell Malignancies |
| Lead sponsor | BioCryst Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | forodesine hydrochloride |
| Start date | Apr 1, 2003 |
| Primary completion | Jan 1, 2005 |
| First posted | Dec 11, 2003 |
| Last update posted | May 30, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: